Dynepo

Definition

Under the name Dynepo, a new erythropoietin (EPO) product for the treatment of anemia resulting from chronic renal failure or chemotherapy in cancer patients was developed using a novel gene activation technology derived from human cells.

The development and licensing of the product is a collaboration between Aventis and Transkaryotic Therapies, Inc. (TKT). Clinical trials are expected to be completed, and the product is projected to be launched in the U.S. and the U.K. in 2003. A patent dispute between Aventis and Amgen has since been resolved in Aventis’ favor.

Significance as a Doping Agent

It is currently not possible to state whether Dynepo is already being misused in sports. The same methodology can be applied for the analytical detection of Dynepo as has already been developed for EPO and its successor product, darbepoetin.

Institute of Biochemistry at the DSHS Cologne, last updated August 23, 2002

UPDATE 2015 Dynepo has not been approved since 2009